NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS) a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that Cellectis will be present at the following upcoming conferences:
Help employers find you! Check out all the jobs and post your resume.
